Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.55 |
| ▸ | GBA1 | P04062 | 12/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3544302 | 0.94 | GBA1 (0.59) | CYP19A1HRH4HRH3GBA1EPHX2 | |
| SCHEMBL10078112 | 0.93 | GBA1 (0.62) | CYP19A1HRH4HRH3GBA1EPHX2 | |
| SCHEMBL14898386 | 0.93 | GBA1 (0.62) | CYP19A1HRH4HRH3GBA1EPHX2 | |
| SCHEMBL5020804 | 0.92 | HRH4 (0.58) | CYP19A1HRH4HRH3GBA1EPHX2 | |
| SCHEMBL15958720 | 0.91 | HRH4 (0.65) | CYP19A1HRH4HRH3GBA1EPHX2 | |
| SCHEMBL5021143 | 0.89 | HRH4 (0.66) | CYP19A1HRH4HRH3GBA1EPHX2 | |
| SCHEMBL21318217 | 0.89 | HRH4 (0.66) | CYP19A1HRH4HRH3GBA1EPHX2 | |
| SCHEMBL18163271 | 0.89 | HRH4 (0.66) | CYP19A1HRH4HRH3GBA1EPHX2 | |
| SCHEMBL5021089 | 0.88 | CYP19A1 (0.59) | CYP19A1HRH4HRH3GBA1 | |
| SCHEMBL19187211 | 0.87 | CYP19A1 (0.51) | CYP19A1HRH4HRH3GBA1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324770-A1 | NITRIFICATION INHIBITORS | THE UNIVERSITY OF MELBOURNE (AU) | 2022-10-13 | — | — | US | claimed |
| EP-4025564-A1 | NITRIFICATION INHIBITORS | The University of Melbourne (AU) | 2022-07-13 | — | — | EP | claimed |
| CN-114616227-A | Nitrification inhibitors | 墨尔本大学 | 2022-06-10 | — | — | CN | claimed |
| WO-2021042169-A1 | NITRIFICATION INHIBITORS | THE UNIVERSITY OF MELBOURNE (AU) | 2021-03-11 | — | — | WO | claimed |
| CN-114616227-B | Nitrification inhibitor | 墨尔本大学 | 2025-01-21 | — | — | CN | disclosed |
| US-20240124371-A1 | NITRIFICATION INHIBITORS AND FORMULATIONS | INCITEC FERTILISERS OPERATIONS PTY LTD (AU) | 2024-04-18 | — | — | US | disclosed |
| US-20220324770-A1 | NITRIFICATION INHIBITORS | THE UNIVERSITY OF MELBOURNE (AU) | 2022-10-13 | — | — | US | disclosed |
| EP-4025564-A1 | NITRIFICATION INHIBITORS | The University of Melbourne (AU) | 2022-07-13 | — | — | EP | disclosed |
| CN-114616227-A | Nitrification inhibitors | 墨尔本大学 | 2022-06-10 | — | — | CN | disclosed |
| WO-2021042169-A1 | NITRIFICATION INHIBITORS | THE UNIVERSITY OF MELBOURNE (AU) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021042169-A1 | NITRIFICATION INHIBITORS | THE UNIVERSITY OF MELBOURNE (AU) | 2021-03-11 | — | — | WO | disclosed |
| US-20200237924-A1 | CONOTOXIN PEPTIDE ANALOGS AND USES FOR THE TREATMENT OF PAIN AND INFLAMMATORY CONDITIONS | KINETA CHRONIC PAIN, LLC (US) | 2020-07-30 | — | — | US | disclosed |
| US-20110223149-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7981999-B2 | Peptidomimetics; kits; macrocyclization | AILERON THERAPEUTICS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100298201-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | AILERON THERAPEUTICS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100216688-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20080262200-A1 | Triazole Macrocycle Systems | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008104000-A2 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262200-A1 | Triazole Macrocycle Systems | FLT3, VIP, NGLY1 | CYP19A1 2366/4885HRH4 1806/4885HRH3 1158/4885 |
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | VIP, ANPEP, DNPEP | CYP19A1 2899/4885HRH4 4460/4885HRH3 3972/4885 |
| US-20110223149-A1 | PEPTIDOMIMETIC MACROCYCLES | PREP, ANPEP, DNPEP | CYP19A1 1866/4885HRH4 4083/4885HRH3 3193/4885 |
| US-20100216688-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | CYP19A1 3811/4885HRH4 4334/4885HRH3 3879/4885 |
| US-20200237924-A1 | CONOTOXIN PEPTIDE ANALOGS AND USES FOR THE TREATMENT OF PAIN AND INFLAMMATORY CONDITIONS | CHRNG, CHRNA9, CHRNA10 | CYP19A1 3743/4885HRH4 1173/4885HRH3 1240/4885 |
| US-20100298201-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | VIP, ANPEP, NGLY1 | CYP19A1 3250/4885HRH4 4246/4885HRH3 3700/4885 |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | PCNA, MKI67, NFATC1 | CYP19A1 2887/4885HRH4 3022/4885HRH3 2281/4885 |
| US-20220324770-A1 | NITRIFICATION INHIBITORS | NOS1, NOS2, NIT2 | CYP19A1 175/4885HRH4 1525/4885HRH3 2479/4885 |
| US-20240124371-A1 | NITRIFICATION INHIBITORS AND FORMULATIONS | NOS1, NOS2, NAT1 | CYP19A1 812/4885HRH4 1769/4885HRH3 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.